End stage renal disease
Conditions
Interventions
Treatment group:Conventional peritoneal dialysis+ dapagliflozin, orally, 1 capsule per time, once a day.
Control group:Conventional peritoneal dialysis
Sponsors
the First Affiliated Hospital of Anhui University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1) Age range of 18-70 years old, male or female not limited; (2) Perform maintenance peritoneal dialysis treatment for more than 3 months; (3) 24 urine output = 400 ml/d; (4) Blood pressure = 120/70mm Hg.
Exclusion criteria
Exclusion criteria: (1) Type 1 diabetes patients; (2) Patients who develop peritonitis within 3 months; (3) Currently receiving SGLT2i treatment or within the past 3 months; (4) Patients with abnormal liver function: ALT or AST>3 times the upper limit of normal, total bilirubin>2 times the upper limit of normal; (5) Repeated severe hypoglycemic reactions (occurring more than twice within a month); (6) History of diabetes ketoacidosis; (7) Allergic to dapagliflozin; (8) Combined symptomatic urinary tract infections; (9) Patients with combined tumors and severe cachexia; (10) Women or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 24-hour urine output, peritoneal ultrafiltration volume, time and incidence of endpoint event (anuria) in patients;Residual kidney GFR;Peritoneum and residual kidney Kt/V; | — |
Secondary
| Measure | Time frame |
|---|---|
| Levels of transforming growth factor - ß (TGF - ß), connective tissue growth factor (CTGF), plasminogen activator inhibitor-1 (PAI-1), and a - smooth muscle actin (a - SMA) in peritoneal dialysis fluid;All-cause mortality, peritonitis, incidence of cardiovascular events, 24-hour average systolic blood pressure (mmHg) and mean diastolic blood pressure (mmHg), weight; | — |
Countries
China
Contacts
Public ContactWang Yiping
the First Affiliated Hospital of Anhui University of Chinese Medicine
Outcome results
None listed